Amid FDA chaos, approval of a rare disease drug gets delayed — again
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly…
Rapamycin Improves PROMs in Patients With ME/CFS in Early Trial
Stephanie L. Grach, MD, MS Credit: Mayo Clinic Weekly rapamycin improved patient-reported outcome measures (PROMs) in patients with…